Lawrence A. Leiter


Associate Scientist, Li Ka Shing Knowledge Institute


Please note: Dr. Leiter is not taking any summer students.

Dr. Lawrence A. Leiter is Director of the Lipid Clinic, Associate Director of the Clinical Nutrition and Risk Factor Modification Centre and an Associate Scientist in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital in Toronto.  From 2000-2010, he was Head of the Division of Endocrinology and Metabolism. He is a Professor in the Departments of Medicine and Nutritional Sciences at the University of Toronto.

Dr. Leiter has several research interests including clinical trials on the prevention of atherosclerosis, especially in diabetes, and the dietary and pharmacologic treatment of diabetes mellitus, hyperlipidemia, hypertension, and obesity. He has over 500 publications in peer-reviewed journals. He was an investigator in many of the landmark diabetes trials including the Diabetes Control and Complications Trial (DCCT), Action to Control Cardiovascular Risk in Diabetes (ACCORD), and Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) and is on the Steering Committees of many ongoing outcome trials in both the diabetes and lipid areas.

Dr. Leiter is the past President of the Canadian Society of Endocrinology & Metabolism (CSEM) and is a past Chair of the Clinical and Scientific Section of the Canadian Diabetes Association (CDA). He has been involved in many national and international committees and consensus conferences including those of the International Diabetes Federation, CDA, Canadian Hypertension Education Program (CHEP), Canadian Cardiovascular Society (Dyslipidemia), and Obesity Canada.

For his work, he has received a number of awards including the CDA Frederick G. Banting Award and the American Diabetes Association Charles H Best Award (awarded to DCCT investigators), both for Distinguished Service. He also received the 2005 CSEM Educator of the Year Award, and the 2006 CDA Gerald S. Wong Award in recognition of significant contributions to the diabetes community. In 2016, Dr. Leiter received the Canadian Diabetes Association Long Term Achievement Award for Research and the Canadian Society of Endocrinology’s Robert Volpe Award. He was also the inaugural winner of the St. Michael’s Hospital Complete Physician Award in 2009.


Recent Publications

  1. Dagenais, GR, Rydén, L, Leiter, LA, Lakshmanan, M, Dyal, L, Probstfield, JL et al.. Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis. Cardiovasc Diabetol. 2020;19 (1):199. doi: 10.1186/s12933-020-01179-1. PubMed PMID:33239067 PubMed Central PMC7690176.
  2. Bhatt, DL, Szarek, M, Steg, PG, Cannon, CP, Leiter, LA, McGuire, DK et al.. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2020; :. doi: 10.1056/NEJMoa2030183. PubMed PMID:33200892 .
  3. Bhatt, DL, Szarek, M, Pitt, B, Cannon, CP, Leiter, LA, McGuire, DK et al.. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med. 2020; :. doi: 10.1056/NEJMoa2030186. PubMed PMID:33200891 .
  4. Ferrannini, G, Gerstein, H, Colhoun, HM, Dagenais, GR, Diaz, R, Dyal, L et al.. Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. Eur Heart J. 2020; :. doi: 10.1093/eurheartj/ehaa777. PubMed PMID:33197271 .
  5. Zurbau, A, Au-Yeung, F, Blanco Mejia, S, Khan, TA, Vuksan, V, Jovanovski, E et al.. Relation of Different Fruit and Vegetable Sources With Incident Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Prospective Cohort Studies. J Am Heart Assoc. 2020;9 (19):e017728. doi: 10.1161/JAHA.120.017728. PubMed PMID:33000670 .
  6. Fitchett, DH, Leiter, LA, Lin, P, Pickering, J, Welsh, R, Stone, J et al.. Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome. CJC Open. 2020;2 (5):402-415. doi: 10.1016/j.cjco.2020.04.002. PubMed PMID:32995726 PubMed Central PMC7499366.
  7. Bays, HE, Banach, M, Catapano, AL, Duell, PB, Gotto, AM Jr, Laufs, U et al.. Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials. J Clin Lipidol. ;14 (5):649-659.e6. doi: 10.1016/j.jacl.2020.08.009. PubMed PMID:32980290 .
  8. Mann, JFE, Hansen, T, Idorn, T, Leiter, LA, Marso, SP, Rossing, P et al.. Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials. Lancet Diabetes Endocrinol. 2020;8 (11):880-893. doi: 10.1016/S2213-8587(20)30313-2. PubMed PMID:32971040 .
  9. Cahn, A, Wiviott, SD, Mosenzon, O, Murphy, SA, Goodrich, EL, Yanuv, I et al.. Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58. Diabetes Obes Metab. 2020; :. doi: 10.1111/dom.14179. PubMed PMID:32844557 .
  10. Garg, V, Verma, S, Connelly, KA, Yan, AT, Sikand, A, Garg, A et al.. Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis. Metabol Open. 2020;7 :100039. doi: 10.1016/j.metop.2020.100039. PubMed PMID:32812924 PubMed Central PMC7424781.
Search PubMed

Affiliations & Other Activities

  • Director, Lipid Clinic, St. Michael’s Hospital
  • Associate Director, Clinical Nutrition and Risk Factor Modification Centre, St. Michael’s Hospital
  • Professor, Departments of Medicine and Nutritional Sciences, University of Toronto